Madrigal Pharmaceuticals (MDGL) Income from Non-Controlling Interests (2023 - 2024)
Madrigal Pharmaceuticals' (MDGL) quarterly Income from Non-Controlling Interests came in at -$196000.0 in Q2 2024, down 6433.33% year-on-year from $3094.7 in Q3 2023, and up 69.38% on a QoQ basis from -$640000.0 in Q1 2024.
Madrigal Pharmaceuticals (MDGL) Income from Non-Controlling Interests (2023 - 2024) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$196000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 16.20 Bn | 15.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -196,000.00 |
| Mar 31, 2024 | -640,000.00 |
| Jun 30, 2023 | -3,000.00 |
| Mar 31, 2023 | -54,000.00 |